Table 1.
The baseline demographics of the trial and registry cohorts
| Characteristics | Trial (n = 2021) | Registry (n = 6790) |
|---|---|---|
| Age category (years), n (%) | ||
| < 20 | 16 (0.8) | 80 (1.2) |
| 20–24 | 76 (3.8) | 273 (4.0) |
| 25–29 | 112 (5.5) | 448 (6.6) |
| 30–34 | 147 (7.3) | 667 (9.8) |
| 35–39 | 251 (12.4) | 797 (11.7) |
| 40–44 | 294 (14.5) | 1003 (14.8) |
| 45–49 | 288 (14.3) | 1026 (15.1) |
| 50–54 | 285 (14.1) | 874 (12.9) |
| 55–59 | 234 (11.6) | 691 (10.2) |
| 60–64 | 155 (7.7) | 413 (6.1) |
| 65–69 | 74 (3.7) | 297 (4.4) |
| 70–74 | 23 (1.1) | 129 (1.9) |
| 75–79 | 7 (0.3) | 66 (1.0) |
| 80–85 | 2 (0.1) | 21 (0.3) |
| > 85 | 1 (0.0) | 5 (0.1) |
| Female, n (%) | 630 (31.2) | 2771 (40.8) |
| Body mass index (kg m−2), mean ± SD | 31.5 ± 10.4 | 31.4 ± 10.6 |
| Alcohol (units per week), mean ± SD | 3.4 ± 5.8 | 8.4 ± 14.0 |
| Smoking (cigarettes per day), n (%) | ||
| Nonsmoker | 1393 (68.9) | 4030 (59.4) |
| Light (< 10) | 192 (9.5) | 487 (7.2) |
| Moderate (10–20) | 203 (10.0) | 834 (12.3) |
| Heavy (≥ 20) | 233 (11.5) | 437 (6.4) |
| Comorbidities, n (%) | ||
| Asthma | 163 (8.1) | 724 (10.7) |
| Hypertension | 551 (27.3) | 1849 (27.2) |
| Angina | 13 (0.6) | 184 (2.7) |
| Myocardial infarction | 35 (1.7) | 166 (2.4) |
| Stroke | 11 (0.5) | 80 (1.2) |
| Diabetes mellitus | 212 (10.5) | 637 (9.3) |
| Depression | 300 (14.8) | 1539 (22.7) |
| Psoriatic arthritis | 559 (27.7) | 1574 (23.2) |
| Ethnicity, n (%) | ||
| Asian | 73 (3.6) | 310 (4.6) |
| Black | 38 (1.9) | 44 (0.6) |
| White | 1871 (92.6) | 6240 (91.9) |
| Other | 39 (1.9) | 187 (2.8) |
| Previous therapies,a mean ± SD | ||
| Systemic therapies | 0.9 ± 1.0 | 1.6 ± 1.0 |
| Biologic therapies | 0.6 ± 0.8 | 0.3 ± 0.6 |
| PASI, mean ± SD | 19.7 ± 7.6 | 15.7 ± 7.8 |
PASI, Psoriasis Area and Severity Index. aPrevious systemic therapies include methotrexate, acitretin, ciclosporin or psoralen–ultraviolet A. Previous biologic therapies include adalimumab, alefacept, efalizumab, etanercept or infliximab in the trial arm, and the above with the addition of ustekinumab or secukinumab in the registry arm.